@satvik_93 Satvik Dasariraju

Satvik Dasariraju posts on X about share, novartis, 100m, $100m the most. They currently have [---] followers and [--] posts still getting attention that total [------] engagements in the last [--] hours.

Engagements: [------] #

[--] Month [-----] -42%
[--] Months [-----] -79%
[--] Year [------] +1,470%

Mentions: [--] #

[--] Months [--] -7.10%
[--] Year [--] +213%

Followers: [---] #

[--] Month [---] +3%
[--] Months [---] +19%
[--] Year [---] +40%

CreatorRank: [---------] #

Social Influence

Social category influence finance stocks fashion brands technology brands automotive brands currencies

Social topic influence share, novartis, 100m, $100m, $39m #3, led, $arwr, in the, fund, happy

Top accounts mentioned or mentioned by @age1vc @novartis @elilillyandco @aginginit @regeneron @norngroup @davidjglassmd @jackomeara @eqts @harvardmed @jeffnippard @bradschoenfeld @rogerfielding5 @gordianbio @bailliegifford @lnuzhna @leportfr @agingjrnl @retrobio @afarorg

Top assets mentioned Novartis AG (NVS) Arrowhead Research Corporation (ARWR) Eli Lilly and Company (LLY) Wave Life Sciences Ltd. Ordinary Shares (WVE) NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) AstraZeneca PLC (AZN) Novo-Nordisk (NVO) Hims & Hers Health, Inc. (HIMS)

Top Social Posts

Top posts by engagements in the last [--] hours

"@_Carol_Mag landslide by fleetwood mac"
X Link 2024-07-19T03:39Z [--] followers, [--] engagements

"Next strategic picks for autologous vs. allogenic therapy. Weighing the risk of additional time to generate patient-derived cells vs. the risk of immune responses for allogenic approaches is critical and the "right call" will vary depending on the organ system being treated and the rate of disease progression"
X Link 2024-08-17T16:05Z [---] followers, [---] engagements

"More broadly in chronic age-related diseases I could see this technology being applied in ways similar to the Beam Tx patent to precisely edit mRNA transcripts to downregulate or upregulate degradation for a target of interest. Of course not every target can be targeted in this way because not every target is like YAP1 where there is an innate highly site-specific degradation system"
X Link 2025-01-24T17:56Z [---] followers, [---] engagements

"Final point: how will these things be delivered For now I could see AAV (intramyocardial injection for something like what Beam Tx might be working on) or LNP-encapsulated editors (like the recent Nvelop Tx + Chroma Medicines = nChroma Bio merger for LNP-encapsulated epigenetic editors)"
X Link 2025-01-24T17:56Z [---] followers, [---] engagements

"Then [--] days ago a genomic medicines lab showed that patient-derived organoids can be used to develop precision ASO therapeutics. Wicked cool. https://www.nature.com/articles/s41586-024-08462-1 https://www.nature.com/articles/s41586-024-08462-1"
X Link 2025-01-26T17:09Z [---] followers, [--] engagements

"ASOs a form of RNA interference have already been transformational in diseases like SMA (nusinersen). Besides delivery the successful application of an ASO comes down to choosing a gene to inhibit (and if the gene is known like in many rare diseases then it's about which exon or intron to promote inclusion or exclusion of)"
X Link 2025-01-26T17:09Z [---] followers, [---] engagements

"Thrilled to announce our next event @aginginit with @NornGroup: the Muscle Aging Science & Translation symposium @harvardmed featuring @davidjglassMD @Regeneron Anne-Ulrike Trendelenburg @Novartis Andrew Adams @EliLillyandCo @JeffNippard @BradSchoenfeld @RogerFielding5 @TuftsUniversity and more RSVP: https://lu.ma/di5165dr https://lu.ma/di5165dr"
X Link 2025-03-12T20:00Z [---] followers, 10.5K engagements

"@olshav @aginginit @NornGroup @harvardmed @davidjglassMD @Regeneron @Novartis @EliLillyandCo @JeffNippard @BradSchoenfeld @RogerFielding5 CMs are welcome too definitely part of the puzzle here"
X Link 2025-03-13T00:03Z [---] followers, [---] engagements

"Super excited for the Muscle Aging symposium next week Joining the star speaker lineup we have the inimitable @LNuzhna Dr. Kenneth Attie @EliLillyandCo and @GordianBio CEO @leportfr. Over [----] signups and seats running out fast https://lu.ma/di5165dr Thrilled to announce our next event @aginginit with @NornGroup: the Muscle Aging Science & Translation symposium @harvardmed featuring @davidjglassMD @Regeneron Anne-Ulrike Trendelenburg @Novartis Andrew Adams @EliLillyandCo @JeffNippard @BradSchoenfeld @RogerFielding5 https://t.co/JIoO2stSxB https://lu.ma/di5165dr Thrilled to announce our next"
X Link 2025-04-12T02:26Z [---] followers, [----] engagements

"A huge thank you to the organizing teams @aginginit @NornGroup and sponsors @EliLillyandCo @Novartis @AgingJrnl @RetroBio_ @AFARorg"
X Link 2025-04-12T02:26Z [---] followers, [--] engagements

"@LNuzhna gave an inspiring perspective on next generation therapeutics to tune gene regulation after which @leportfr showcased the @GordianBio platform and in vivo pooled screening for translational discovery in osteoarthritis. Two founders on the frontier ushering in a new era for chronic disease care"
X Link 2025-04-21T17:53Z [---] followers, [----] engagements

"We heard from industry leaders @davidjglassMD @Regeneron Anne-Ulrike Trendelenburg @Novartis and Ken Attie alongside Andrew Adams @EliLillyandCo. A masterclass on topics like bimagrumab target discovery genetic medicines and much more from the absolute best in the business"
X Link 2025-04-21T17:53Z [---] followers, [---] engagements

"A massive thank you to sponsors @EliLillyandCo @Novartis @AFARorg @RetroBio_ @AgingJrnl @NornGroup our incredible speakers and to everyone who made the trek out to Boston to attend It was really humbling to organize the Muscle Aging Symposium with my team @aginginit alongside @NornGroup last week. Truly so much heavy lifting ahead of us in therapeutic development for the muscle metabolism and frailty spaces but some exciting tailwinds https://t.co/xBXIryJSeO It was really humbling to organize the Muscle Aging Symposium with my team @aginginit alongside @NornGroup last week. Truly so much"
X Link 2025-04-21T18:03Z [---] followers, [---] engagements

"@davidjglassMD @Regeneron @Novartis @EliLillyandCo 🙏"
X Link 2025-04-21T18:35Z [---] followers, [--] engagements

"Big news in the muscle and metabolic health world today from @Regeneron - a one-two punch. First they get a Ph3 ready GLP-1/GIP agonist for $80M upfront from Hansoh. On top of this being a potential (late) tirzepatide competitor the main unlock here is it opens up a wide range of entirely proprietary drug combos: incretins + one of: MSTN mAb in (sarcopenic) obesity PDGFR mAb for PAH NPR1 agonist for hypertension LEPR agonist for lipodystrophy etc. https://www.fiercebiotech.com/biotech/regeneron-pens-2b-pact-hansohs-potential-rival-zepbound"
X Link 2025-06-02T16:01Z [---] followers, [----] engagements

"Huge news as FDA agrees to hip BMD as a primary endpoint for a pivotal trial in postmenopausal osteoporosis. Unclear if this is specific to PTH mechanism (which has years of real-world data from teriparatide); either way it portends well for the FDA's review of SABRE for BMD as an approvable endpoint in general. https://investors.enterabio.com/news-releases/news-release-details/entera-bio-receives-fda-agreement-bmd-primary-endpoint-eb613 https://investors.enterabio.com/news-releases/news-release-details/entera-bio-receives-fda-agreement-bmd-primary-endpoint-eb613"
X Link 2025-07-28T22:56Z [---] followers, [----] engagements

"The ultimate oral combo for MASH Madrigal in-licenses a preclinical oral small molecule GLP-1 receptor agonist from China's CSPC (it's an orforglipron derivative) likely to pair with resmetirom. https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-enters-exclusive-global-license https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-enters-exclusive-global-license"
X Link 2025-07-30T11:31Z [---] followers, [---] engagements

"upfront payment of $120 million for a PCC 🤯"
X Link 2025-07-30T11:34Z [---] followers, [--] engagements

"insane premium for oral small molecules for this class the Hansoh-Regeneron deal was $80M upfront for a phase [--] ready GLP-1/GIP dual agonist (injectable)"
X Link 2025-07-30T11:37Z [---] followers, [---] engagements

"ANGPTL3 space is heating up more news today: https://www.fiercebiotech.com/biotech/novartis-returns-argo-multi-faceted-5b-cardiovascular-collab What is the endgame for ANGPTL3 $LLY in their website update just added VERVE-201 alongside the PCSK9 editor VERVE-102 in their list of phase [--] programs. With ANGPTL3 the siRNA results ($LLY $ARWR) have been quite different from the ASO data (Ionis). It'll be intriguing to https://t.co/XlzThtUgUi https://www.fiercebiotech.com/biotech/novartis-returns-argo-multi-faceted-5b-cardiovascular-collab What is the endgame for ANGPTL3 $LLY in their website"
X Link 2025-09-03T17:31Z [---] followers, [---] engagements

"Generally excited about RNA editing. While cell type-specific transcription factor reprogramming (NewLimit among others) is undoubtedly going to play a role in the longevity biotech story RNA editing lets you get really specific to the level of specific transcripts. Transcription factors by nature have broader effects on cells (which is part of the appeal for companies trying to holistically "rejuvenate" older cells towards a younger cell state)"
X Link 2025-01-24T17:56Z [---] followers, [---] engagements

"For the rare disease space Wave Life Sciences is already in the clinic with the first-ever RNA editing drug candidate (A-to-I editing to correct a G-to-A point mutation in the SERPINA1 gene for Alpha-1 Antitrypsin Deficiency: https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-announces-initiation-dosing-restoraation https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-announces-initiation-dosing-restoraation"
X Link 2025-01-24T17:56Z [---] followers, [---] engagements

"What is the endgame for ANGPTL3 $LLY in their website update just added VERVE-201 alongside the PCSK9 editor VERVE-102 in their list of phase [--] programs. With ANGPTL3 the siRNA results ($LLY $ARWR) have been quite different from the ASO data (Ionis). It'll be intriguing to follow how far (how preventative how broad in ASCVD) ANGPTL3 inhibition can go given that there's some overlap in the PD with other approved medicines. Solbinsiran Lilly's Phase [--] siRNA is being developed for mixed dyslipidemia. They clearly like what they see because there's the siRNA an anti-ANGPTL3/8 antibody and also"
X Link 2025-08-12T19:05Z [---] followers, [----] engagements

"@Jack_O_Meara @yaireinhorn @WaveLifeSci No clinical data yet besides TE from $WVE they indicated weight loss data would come cohort by cohort likely starting Q4 [----]. $ARWR would be next"
X Link 2025-11-08T15:38Z [---] followers, [---] engagements

"This is gonna be SAD cohorts [--] and [--] (3 month follow up) in overweight/obese non-diabetics. Aggressive move to announce data this week maybe we expect VAT reduction and lean mass no change Over/under 1.2% weight loss in [--] weeks Semaglutide hits 2.5% placebo-adjusted weight loss at [--] weeks. https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-announce-interim-data-phase-1-inlight-trial https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-announce-interim-data-phase-1-inlight-trial"
X Link 2025-12-07T22:46Z [---] followers, [----] engagements

"So the math maybe puts you at 1-2%. The human genetics suggests no effect on weight but that's lifelong inhibition vs. lipolysis induction at a discrete point in time in individuals with substantial fat mass"
X Link 2025-12-07T22:52Z [---] followers, [---] engagements

"Math aside there's no reason for $WVE to do this unless they have more than 1/2 of semaglutide weight loss in the same period with lean mass preservation so that'd be what I'd center my prior on"
X Link 2025-12-07T22:53Z [---] followers, [---] engagements

"0.9% placebo-adjusted body weight loss (I guessed 1.2%). Main thing is VAT reduction. This is gonna be SAD cohorts [--] and [--] (3 month follow up) in overweight/obese non-diabetics. Aggressive move to announce data this week maybe we expect VAT reduction and lean mass no change Over/under 1.2% weight loss in [--] weeks Semaglutide hits 2.5% placebo-adjusted weight This is gonna be SAD cohorts [--] and [--] (3 month follow up) in overweight/obese non-diabetics. Aggressive move to announce data this week maybe we expect VAT reduction and lean mass no change Over/under 1.2% weight loss in [--] weeks"
X Link 2025-12-08T12:54Z [---] followers, [---] engagements

"The graph shows [--] mpk bima which we know is less optimal than [--] mpk"
X Link 2025-12-08T12:55Z [---] followers, [--] engagements

"Ziltivekimab Phase [--] (IL-6 mAb): can inhibiting systemic inflammation reduce CV events in high ASCVD risk patients with residual inflammation and (unlike IL-1b inhibition) can this be done without increasing susceptibility to fatal infections The post-MI and HF trials will also readout in '26 or '27"
X Link 2026-01-01T18:41Z [---] followers, [---] engagements

"$ARWR and $WVE Phase 1/2 readouts (INHBE GalNAc-siRNA and adipose-targeted Alk7 siRNA): (1) will modulating fat distribution and preventing fat accumulation lead to sufficiently deep and swift reduction of regulatory endpoint-related measures (2) is adipose delivery to siRNA solved (3) how might the market react to clear reductions in VAT and other metabolic risk factors without major changes to regulatory endpoints in obesity/diabetes (HbA1c total body weight) https://twitter.com/i/web/status/2006798054502904100 https://twitter.com/i/web/status/2006798054502904100"
X Link 2026-01-01T18:41Z [---] followers, [---] engagements

"AMG [---] Phase [--] (FAM13A siRNA unclear if it is liver and/or adipose targeted): how will the human genetics signal of favorable adiposity (e.g. reduced VAT/SAT ratio) manifest in the clinic. Similar to INHBE/Alk7 in continuing the trend of going beyond just weight in obesity"
X Link 2026-01-01T18:41Z [---] followers, [---] engagements

"And of course $NAMS CETP inhibitor with the Phase [--] outcomes readout"
X Link 2026-01-04T00:20Z [---] followers, [---] engagements

"Congratulations to @loyalfordogs as they continue to make big strides in this new path they're charting The Series C announcement follows FDA Center for Veterinary Medicine acceptance of two of three major requirements needed for LOY-002s Expanded Conditional Approval application. Were excited to share weve raised $100M in Series C funding bringing our total investment to over $250M. Led by @age1vc with participation from @BaillieGifford and existing investors this funding will help us move from late-stage development to market readiness for LOY-002. https://t.co/NmVAhjLsBl Were excited to"
X Link 2026-02-11T15:11Z [---] followers, [---] engagements

"I'd also add the many NLRP3 molecules which will likely yield data next year the relaxin mimetics from $AZN and $TECX for HF subsets and $NVO and $LLY testing the long-acting natriuretic peptide hypothesis in HF"
X Link 2026-01-01T18:41Z [---] followers, [---] engagements

"Big milestone today in Aerska's mission to advance systemically-administered RNA medicines for neurodegenerative disease. @Jack_O_Meara and team are moving at lightning speed ⚡ Very happy to share that we co-led Aerska's $39M Series A with @eqt's Dementia Fund Neurodegeneration has robbed us of too much. Time to fight back $60M to date for Aerska by @Jack_O_Meara in just a couple months over one year of existing We movin. Very happy to share that we co-led Aerska's $39M Series A with @eqt's Dementia Fund Neurodegeneration has robbed us of too much. Time to fight back $60M to date for Aerska"
X Link 2026-02-09T15:32Z [---] followers, [---] engagements

"Coming off of last week where we announced we @age1vc led Loyal's $100M Series C and co-led Aerska's $39M Series A we're thinking a lot about what areas we want to invest in next. 🧵"
X Link 2026-02-16T15:21Z [---] followers, [---] engagements

"Excited to share a few spaces we think are underbuilt relative to how much theyll matter over the next decade - five defining frontiers of biotech preventative therapeutics and age-related disease in the 2030s https://www.librariesforthefuture.bio/p/five-unconquered-frontiers-for-longevity https://www.librariesforthefuture.bio/p/five-unconquered-frontiers-for-longevity"
X Link 2026-02-16T15:21Z [---] followers, [---] engagements

"Speaker event with genomics and metabolic disease expert Professor Melina Claussnitzer on 2/26/2026 4-5pm Learn how big data and human genetics fuels discovery of new targets for obesity diabetes and other population-scale cardiometabolic diseases"
X Link 2026-02-11T22:11Z [---] followers, [---] engagements

"Loyal has raised a $100M Series C from age1 Baillie Gifford existing investors & more this brings Loyal's total funding to over a quarter of a billion dollars we are building the longevity pharma starting with dog longevity. thanks @FastCompany for the exclusive -"
X Link 2026-02-11T15:03Z 33.4K followers, 48.5K engagements

"Were excited to share weve raised $100M in Series C funding bringing our total investment to over $250M. Led by @age1vc with participation from @BaillieGifford and existing investors this funding will help us move from late-stage development to market readiness for LOY-002"
X Link 2026-02-11T14:11Z [----] followers, 50.5K engagements

"Very happy to share that we co-led Aerska's $39M Series A with @eqt's Dementia Fund Neurodegeneration has robbed us of too much. Time to fight back $60M to date for Aerska by @Jack_O_Meara in just a couple months over one year of existing We movin"
X Link 2026-02-09T15:08Z [----] followers, [----] engagements

"RT @AlexJColville: Very happy to share that we co-led Aerska's $39M Series A with @eqt's Dementia Fund Neurodegeneration has robbed us of"
X Link 2026-02-09T15:27Z [---] followers, [--] engagements

"Biotech doubles financing in quest to silence genes behind neurological diseases via @statnews https://www.statnews.com/2026/02/09/aerska-therapeutics-biotech-financing/ https://www.statnews.com/2026/02/09/aerska-therapeutics-biotech-financing/"
X Link 2026-02-09T13:09Z 110.5K followers, 23.4K engagements

"Launching the third piece of a 5-part series for founders & scientists on target discovery - why preserving physiological context can determine the successof your screen. Shout out to @GordianBio @FaunaBio @peel_tx & @ochrebio for inspiration. https://open.substack.com/pub/age1/p/hunting-targets-in-their-native-environmentr=39mr9r&utm_medium=ios&shareImageVariant=overlay https://open.substack.com/pub/age1/p/hunting-targets-in-their-native-environmentr=39mr9r&utm_medium=ios&shareImageVariant=overlay"
X Link 2026-02-07T19:05Z [--] followers, [----] engagements

"Today the FDA is announcing its intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies including Hims & Hers and other compounding pharmacies as similar https://t.co/2KMBRodPvV Today the FDA is announcing its intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies including Hims & Hers and other compounding pharmacies as similar https://t.co/2KMBRodPvV"
X Link 2026-02-06T22:39Z [---] followers, [---] engagements

"Today the FDA is announcing its intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies including Hims & Hers and other compounding pharmacies as similar alternatives to FDA-approved drugs. https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs"
X Link 2026-02-06T21:59Z 589.1K followers, 358.5K engagements

"RT @sapinker: "An open project to accelerate healthy longevity." A gorgeous fascinating and vitally important new report by my former stu"
X Link 2026-02-02T16:06Z [---] followers, [--] engagements

""An open project to accelerate healthy longevity." A gorgeous fascinating and vitally important new report by my former student Dr. Raiany Romanni on how even small slowdowns in the aging process could have massive benefits. No nonsense about immortality supplements fasting the singularity uploading your connectome to the cloud or other flimflam just clear and coolheaded analysis. How could tiny breakthroughs in aging science change U.S. GDP and population growth Whats the economic value of making [--] the new [--] or [--] the new [--] How many lives could we create or save if we could slow"
X Link 2026-01-30T02:36Z 857.8K followers, 23.9K engagements

"How could tiny breakthroughs in aging science change U.S. GDP and population growth Whats the economic value of making [--] the new [--] or [--] the new [--] How many lives could we create or save if we could slow reproductive or brain aging by just [--] year What would billions of healthier hours be worth to the economy if we assume no change in the age of retirement I spent the last two years obsessing over the design research and execution of this project. The result is a book upcoming with Harvard University Press a preprint andmaybe your favorite partan interactive simulation tool that lets you"
X Link 2026-01-28T15:03Z [----] followers, 1M engagements

"Starting something new: Approved a biotech podcast I'm co-hosting with Matthew Pech. Our first episode covers Amylin Pharmaceuticals: the pioneers of the GLP-1 drug class"
X Link 2026-01-30T16:52Z [----] followers, 37.7K engagements

"Re: the continued primacy of human genetics in drug development practitioners' toolbox for target selection the core reasons could be that this approach moves human biology and causality as early as possible in asset development. 🧵 Biology is hard betting on it is harder. Launching the first piece of a 5-part series for founders & scientists trying to find the successful target: https://t.co/7BtoCqQO4a Big thanks to @age1vc crew - genuinely fun building this:) Biology is hard betting on it is harder. Launching the first piece of a 5-part series for founders & scientists trying to find the"
X Link 2026-01-21T16:07Z [---] followers, [----] engagements

"Biology is hard betting on it is harder. Launching the first piece of a 5-part series for founders & scientists trying to find the successful target: Big thanks to @age1vc crew - genuinely fun building this:) https://open.substack.com/pub/age1/p/betting-on-biology-part-ir=39mr9r&utm_medium=ios&shareImageVariant=overlay https://open.substack.com/pub/age1/p/betting-on-biology-part-ir=39mr9r&utm_medium=ios&shareImageVariant=overlay"
X Link 2026-01-21T14:10Z [--] followers, [----] engagements

"Well-known examples include: waist-hip ratio adjusted for BMI which yielded INHBE and ACVR1C; remnant cholesterol (TC - LDL - HDL) which underlies the ANGPTL4 story. More on this front to come"
X Link 2026-01-21T16:07Z [---] followers, [---] engagements

"Another area that MR/GWAS has not come close to exhaustively searching is tissue-specific eQTLs and caQTLs (e.g. for genetic variants that express in cardiomyocytes and in doing so causally confer increased or decreased risk for heart conditions)"
X Link 2026-01-21T16:07Z [---] followers, [---] engagements

"Awesome primer on target selection by @LynettaWang126 Great nuggets on MR/GWAS causality and compensatory mechanisms. Part [--] of a fabulous 5-part series Biology is hard betting on it is harder. Launching the first piece of a 5-part series for founders & scientists trying to find the successful target: https://t.co/7BtoCqQO4a Big thanks to @age1vc crew - genuinely fun building this:) Biology is hard betting on it is harder. Launching the first piece of a 5-part series for founders & scientists trying to find the successful target: https://t.co/7BtoCqQO4a Big thanks to @age1vc crew - genuinely"
X Link 2026-01-21T15:33Z [---] followers, [---] engagements

"what are the most important problems in therapeutics [--] stand out: - discovering new targets - delivering expressive medicines to the right cells - generating OOMs more human data other challenges like improving predictive validity or clinical success rates follow from these"
X Link 2026-01-20T16:46Z [----] followers, [---] engagements

"Super excited to share that the @aginginit is hosting an event focused on osteoarthritis biology surgery and therapeutics. Despite almost 1B people projected to have OA by [----] there are no approved disease-modifying therapies pointing to the pressing need and opportunity for innovation. Registrations have just opened https://luma.com/kb5j2ce5 https://luma.com/kb5j2ce5"
X Link 2026-01-15T18:17Z [---] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing